CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon

Infection, Genetics and Evolution

Volumn 35, Issue , 2015, Pages 122-126

  Paganotti, Giacomo Maria ^a,b,c   Russo, Gianluca ^c   Sobze, Martin Sanou ^d   Mayaka, George Bouting ^e   Muthoga, Charles Waithaka ^a,b   Tawe, Leabaneng ^a,b   Martinelli, Axel ^f   Romano, Rita ^c   Vullo, Vincenzo ^c  

^a BOTSWANA UPENN PARTNERSHIP   (Botswana)

^b Medical Education Partnership Initiative (MEPI) Laboratory   (Botswana)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF DSCHANG   (Cameroon)

^e District Hospital of Dschang   (Cameroon)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Cameroon; CYP2B6; Efavirenz; Nevirapine; Pharmacogenetics; Poor metabolisers

Indexed keywords

EFAVIRENZ; NEVIRAPINE; BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN; CYTOCHROME P450 2B6;

ADULT; ARTICLE; CAMEROON; CHILD; CONTROLLED STUDY; CYP2B6 GENE; DRUG METABOLISM; GENE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; ADOLESCENT; BLACK PERSON; CROSS-SECTIONAL STUDY; GENETICS; HIV INFECTIONS; INFANT; PERSONALIZED MEDICINE; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; CAMEROON; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2B6; GENE FREQUENCY; HIV INFECTIONS; HUMANS; INFANT; NEVIRAPINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; YOUNG ADULT;

EID: 84939157262     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2015.08.003     Document Type: Article

References (51)

1. Baggaley R.F., Garnett G.P., Ferguson N.M. Modelling the impact of antiretroviral use in resource poor settings. PLoS Med. 2006, 3(4):e124.
2. Bertrand J., Chou M., Richardson D.M., Verstuyft C., Leger P.D., Mentré F., Taburet A.M., Taburet D.W. ANRS 12154 study group. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet. Genomics 2012, 22(12):868-876.
3. Campbell M.C., Tishkoff S.A. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Ann. Rev. Genomics Hum. Genet. 2008, 9:403-433.
4. Chen J., Sun J., Ma Q., Yao Y., Wang Z., Zhang L., Li L., Sun F., Lu H. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther. Drug Monit. 2010, 32(5):573-578.
5. CNLS (Comité National de Lutte contre le SIDA)/UNAIDS (United Nation against AIDS), Yaoundé, Cameroon: Global Aids Response Progress (GARP), 2014. (accessed 7 November 2014). http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries/CMR_narrative_report_2014.pdf.
6. Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 2002, 3(6):561-597.
7. Excoffier L., Lischer H.E. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 2010, 10(3):564-567.
8. Frasco M.A., Mack W.J., Van Den Berg D., Aouizerat B.E., Anastos K., Cohen M., De Hovitz J., Golub E.T., Greenblatt R.M., Liu C., Conti D.V., Pearce C.L. Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. AIDS 2012, 26(16):2097-2106.
9. Gonzalez F.J., Nebert D.W. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet. 1990, 6(6):182-186.
10. Grimsrud A., Balkan S., Casas E.C., Lujan J., Van Cutsem G., Poulet E., Myer L., Pujades-Rodriguez M. Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs. J. Acquir. Immune Defic. Syndr. 2014, 67(2):e55-e66.
11. Habtewold A., Amogne W., Makonnen E., Yimer G., Riedel K.D., Ueda N., Worku A., Haefeli W.E., Lindquist L., Aderaye G., Burhenne J., Aklillu E. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother. 2011, 66(10):2350-2361.
12. Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., Acosta E. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS 2004, 18(18):2391-2400.
13. Haas D.W., Gebretsadik T., Mayo G., Menon U.N., Acosta E.P., Shintani A., Floyd M., Stein C.M., Wilkinson G.R. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 2009, 199(6):872-880.
14. Haas D.W., Severe P., Jean Juste M.A., Pape J.W., Fitzgerald D.W. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. J. Antimicrob. Chemother. 2014, 69(8):2187-2190.
15. *6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 2008, 325(1):284-292.
16. Ikediobi O., Aouizerat B., Xiao Y., Gandhi M., Gebhardt S., Warnich L. Analysis of pharmacogenetic traits in two distinct South African populations. Hum. Genomics 2011, 5(4):265-282.
17. Klein K., Lang T., Saussele T., Barbosa-Sicard E., Schunck W.H., Eichelbaum M., Schwab M., Zanger U.M. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 2005, 15(12):861-873.
18. Kwara A., Ramachandran G., Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin. Drug Metab. Toxicol. 2010, 6(1):55-68.
19. Lavandera J.V., Parera V.E., Rossetti M.V., Batlle A., Buzaleh A.M. Identification of CYP3A5 and CYP2B6 polymorphisms in porphyria cutanea tarda associated to human immunodeficiency virus. J. Clin. Exp. Dermatol. Res. 2011, S2:006.
20. Lee K.Y., Lin S.W., Sun H.Y., Kuo C.H., Tsai M.S., Wu B.R., Tang S.Y., Liu W.C., Chang S.Y., Hung C.C. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PLoS One 2014, 9(2):e88497.
21. Lehr T., Yuan J., Hall D., Zimdahl-Gelling H., Schaefer H.G., Staab A., MacGregor T.R., Jayadev S. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet. Genomics 2011, 21(11):721-730.
22. Lubomirov R., Colombo S., di Iulio J., Ledergerber B., Martinez R., Cavassini M., Hirschel B., Bernasconi E., Elzi L., Vernazza P., Furrer H., Günthard H.F., Telenti A. Swiss HIV cohort study. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis. 2011, 203(2):246-257.
23. Mehlotra R.K., Ziats M.N., Bockarie M.J., Zimmerman P.A. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 2006, 62(4):267-275.
24. Micheli J.E., Chinn L.W., Shugarts S.B., Patel A., Martin J.N., Bangsberg D.R., Kroetz D.L. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?. Pharmacogenet. Genomics 2013, 23(11):591-596.
25. *6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 2009, 68(5):690-699.
26. Mukonzo J.K., Okwera A., Nakasujja N., Luzze H., Sebuwufu D., Ogwal-Okeng J., Waako P., Gustafsson L.L., Aklillu E. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect. Dis. 2013, 13:261.
27. Mukonzo J.K., Owen J.S., Ogwal-Okeng J., Kuteesa R.B., Nanzigu S., Sewankambo N., Thabane L., Gustafsson L.L., Ross C., Aklillu E. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One 2014, 9(1):e86919.
28. Nebert D.W., Nelson D.R., Feyereisen R. Evolution of the cytochrome P450 genes. Xenobiotica 1989, 19(10):1149-1160.
29. Ngaimisi E., Habtewold A., Minzi O., Makonnen E., Mugusi S., Amogne W., Yimer G., Riedel K.D., Janabi M., Aderaye G., Mugusi F., Bertilsson L., Aklillu E., Burhenne J. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two Sub-Saharan Africa populations. PLoS One 2013, 8(7):e67946.
30. *6) variant and effect on the population pharmacokinetics of efavirenza in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 2008, 64(4):357-365.
31. Penzak S.R., Kabuye G., Mugyenyi P., Mbamanya F., Natarajan V., Alfaro R.M., Kityo C., Formentini E., Masur H. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 2007, 8(2):86-91.
32. Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., Clifford D.B., Marzolini C., Fletcher C.V., Tashima K.T., Kuritzkes D.R., Acosta E.P. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin. Infect. Dis. 2006, 42(3):401-407.
33. Ribaudo H.J., Liu H., Schwab M., Schaeffeler E., Eichelbaum M., Motsinger-Reif A.A., Ritchie M.D., Zanger U.M., Acosta E.P., Morse G.D., Gulick R.M., Robbins G.K., Clifford D., Haas D.W. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. J. Infect. Dis. 2010, 202(5):717-722.
34. Riska P., Lamson M., MacGregor T., Sabo J., Hattox S., Pav J., Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 1999, 27(8):895-901.
35. Rodriguez-Novoa S., Barreiro P., Rendón A., Jiménez-Nacher I., González-Lahoz J., Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 2005, 40(9):1358-1361.
36. Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Décosterd L., Blievernicht J., Saussele T., Günthard H.F., Schwab M., Eichelbaum M., Telenti A., Zanger U.M. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 2007, 81(4):557-566.
37. Saitoh A., Sarles E., Capparelli E., Aweeka F., Kovacs A., Burchett S.K., Wiznia A., Nachman S., Fenton T., Spector S.A. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007, 21(16):2191-2199.
38. Sarfo F.S., Zhang Y., Egan D., Tetteh L.A., Phillips R., Bedu-Addo G., Sarfo M.A., Khoo S., Owen A., Chadwick D.R. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J. Antimicrob. Chemother. 2014, 69(2):491-499.
39. Stadeli K.M., Richman D.D. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir. Ther. 2013, 18(1):115-123.
40. Stephens M., Smith N., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68(4):978-989.
41. Swart M., Skelton M., Wonkam A., Kannemeyer L., Chin'ombe N., Dandara C. CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two bantu-speaking populations from Cameroon and South Africa: implications for global pharmacogenetics. Curr. Pharmacogenomics Person Med. 2012, 10(1):43-53.
42. ter Heine R., Scherpbier H.J., Crommentuyn K.M., Bekker V., Beijnen J.H., Kuijpers T.W., Huitema A.D. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir. Ther. 2008, 13(6):779-787.
43. Turriziani O., Russo G., Lichtner M., Strano A., Tsague G., Maida P., Vullo V., Antonelli G. Study of the genotypic resistant pattern in HIV-infected women and children from rural west-Cameroon. AIDS Res. Hum. Retroviruses 2008, 24(6):781-785.
44. Wang J., Sönnerborg A., Rane A., Josephson F., Lundgren S., Ståhle L., Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 2006, 16(3):191-198.
45. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003, 306(1):287-300.
46. WHO: the HIV drug resistance report, 2012. (accessed 17 Oct 2014). http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf.
47. WHO: consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013. (accessed 17 Oct 2014). http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
48. Wortham M., Czerwinski M., He L., Parkinson A., Wan Y.J. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab. Dispos. 2007, 35(9):1700-1710.
49. Wyen C., Hendra H., Vogel M., Hoffmann C., Knechten H., Brockmeyer N.H., Bogner J.R., Rockstroh J., Esser S., Jaeger H., Harrer T., Mauss S., van Lunzen J., Skoetz N., Jetter A., Groneuer C., Fätkenheuer G., Khoo S.H., Egan D., Back D.J., Owen A. German competence network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 2008, 61(4):914-918.
50. Wyen C., Hendra H., Siccardi M., Platten M., Jaeger H., Harrer T., Esser S., Bogner J.R., Brockmeyer N.H., Bieniek B., Rockstroh J., Hoffmann C., Stoehr A., Michalik C., Dlugay V., Jetter A., Knechten H., Klinker H., Skaletz-Rorowski A., Fätkenheuer G., Egan D., Back D.J., Owen A. German Competence Network for HIV/AIDS Coordinators. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 2011, 66(9):2092-2098. 10.1093/jac/dkr272.
51. Yuan J., Guo S., Hall D., Cammett A.M., Jayadev S., Distel M., Storfer S., Huang Z., Mootsikapun P., Ruxrungtham K., Podzamczer D., Haas D.W. Nevirapine Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011, 25(10):1271-1280.